Insilico’s big gain after Hong Kong listing: Finance Report
Plus: Radiopharma play Aktis looks to NASDAQ for IPO, and more
As 2025 came to a close, Insilico priced the biggest Hong Kong IPO of the year by a biotech, raising nearly HK$3.3 billion ($292.6 million) in an offering it described as “massively oversubscribed.” Its shares also performed strongly in the aftermarket, rising 56% by Friday’s close.
Founded in 2014, Insilico Medicine Inc. (HKEX:3696) has built a portfolio of internally developed therapies while also bringing in revenue via discovery partnerships based on its generative AI technologies. Its clinical candidates include treatments for idiopathic pulmonary fibrosis, inflammatory bowel disease and cancer; it has out-licensed products to Exelixis Inc. (NASDAQ:EXEL) and Menarini Group; forged a co-development pact with Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196); and entered discovery deals with a host of pharmas, including Eli Lilly and Co. (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck KGaA (Xetra:MRK) and Sanofi (Euronext:SAN; NASDAQ:SNY)...